Long term administration of Hypericum perforatum improves spatial learning and memory in the water maze

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 10, 2002, Pages 1289-1294

  Widy Tyszkiewicz, Ewa ^a   Piechal, Agnieszka ^a   Joniec, Ilona ^a   Blecharz Klin, Kamilla ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

5 hydroxytryptamine; Hypericum perforatum; Monoamine; Prefrontal cortex; Spatial memory; Water maze

Indexed keywords

HERBACEOUS AGENT; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; HYPERICUM PERFORATUM; HYPOTHALAMUS; LEARNING; MALE; MAZE TEST; MEMORY; NONHUMAN; PREFRONTAL CORTEX; RAT; SEROTONIN BRAIN LEVEL; ANIMAL; BRAIN; DRUG EFFECT; ESCAPE BEHAVIOR; HYPERICUM; MEDICINAL PLANT; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BRAIN; ESCAPE REACTION; HYPERICUM; MALE; MAZE LEARNING; MEMORY; PLANTS, MEDICINAL; RATS; RATS, WISTAR;

EID: 0036780634     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.1289     Document Type: Article

References (42)

1. Linde K., Ramirez G., Mulrow C. D., Pauls A., Weidenhammer W., Melchart D., Brit. Med. J., 313, 253-258 (1996).
2. Williams J., Mulrow C. D., Chiquette E., Noël P. H., Aguilar C., Cornell J., Ann. Int. Med., 132, 743-756 (2000).
3. Brenner R., Azbel V. M., Madhusoodanan S., Pawlowska M., Clin. Ther., 22, 411-419 (2000).
4. Woelk H., Brit. Med. J., 321, 536-539 (2000).
5. Hubner W. D., Kirste T., Psychother. Res., 15, 367-370 (2001).
6. Gaster B., Holroyd J., Arch. Int. Med., 160, 152-156 (2000).
7. Butterweck V., Jürgenliemk G., Nahrstedt A., Winterhoff H., Planta Medica, 66, 3-6 (2000).
8. De Vry J., Maurel S., Schreiber R., de Beun R., Jentzsch K. R., Eur. Neuropsychopharmacol., 9, 461-468 (1999).
9. Gambarana C., Ghiglieri O., Tolu P., De Montis G., Giachetti D., Bombardelli E., Tagliamonte A., Neuropsychopharmacology, 21, 247-257 (1999).
10. Oztürk Y., Pharmacopsychiatry, 30 (Suppl. 2), S125-S128 (1997).
11. Panocka I., Perfumi M., Angeletti S., Ciccocioppo R., Massi M., Pharmacol. Biochem. Behav., 66, 105-111 (2000).
12. Vandenbogaerde A., Zanoli P., Puia G., Truzzi C., Kamuhabwa A., De Witte P., Merlevede W., Braldi M., Pharmacol. Biochem. Behav., 65, 627-633 (2000).
13. Kumar V., Singh P. N., Muruganandam A. V., Bhattacharya S. K., J. Ethnopharmacol., 72, 119-128 (2000).
14. Klusa V., Germane S., Nöldner M., Chatterjee S. S., Pharmacopsychiatry, 34 (Suppl. 1), S61-S69 (2001).
15. Doris A., Ebmeier K., Shajahan P., Lancet, 354, 1369-1375 (1999).
16. Widy-Tyszkiewicz E., Scheel-Krüger J., Christensen A. V., Behav. Brain Res., 54, 179-185 (1993).
17. Glowinski J., Iversen I. L., J. Neurochem., 13, 655-669 (1966).
18. Khalifa A. E., J. Ethnopharmacol., 76, 49-57 (2001).
19. Misane I., Ögren S., Pharmacopsychiatry, 34 (Suppl. 1), S89-S97 (2001).
20. Lehrl S., Willemsen A., Papp R., Woelk H., Nervenheilkunde, 12, 281-284 (1993).
21. Johnson D., Ksciuk H., Woelk H., Sauerwein-Giese E., Frauendorf A., J. Geriatr. Psych. Neurol., 7 (Suppl. 1), S44-S46 (1994).
22. Dimpfel W., Todorova A., Vonderheid-Guth B., Eur. J. Med. Res., 4, 303-312 (1999).
23. Schellenberg R., Sauer S., Dimpfel W., Pharmacopsychiatry, 31 (Suppl. 1), S44-S53 (1998).
24. Schulz H., Jobert M., J. Geriatr. Psychiatry Neurol., 7 (Suppl. 1), S39-S43 (1994).
25. Delgado P., Moreno F., Int. Clin. Psychopharmacol., 14 (Suppl. 1), S9-S16 (1999).
26. Calapai G., Crupi A., Firunzeoli F., Costantino G., Inferrera G., Campo G. M., Caputi A. P., J. Pharm. Pharmacol., 51, 723-728 (1999).
27. Calapai G., Crupi A., Firunzeoli F., Inferrera G., Squadrito F., Parisi A., De Sarro G., Caputi A., Pharmacopsychiatry, 34, 45-49 (2001).
28. Gobbi M., Dalla Valle F., Ciapparelli C., Diomede L., Paolo Morazzoni P., Verotta L., Caccia S., Cervo L., Mennini T., Arch. Pharmacol., 360, 262-269 (1999).
29. Yu P. H., Pharmacopsychiatry, 33, 60-65 (2000).
30. Nahrstedt A., Butterweck V., Pharmacopsychiatry, 30 (Suppl. 2), S129-S134 (1997).
31. O'Keefe J., Prog. Neurobiol., 13, 419-439 (1979).
32. Winocur G., Psychobiology, 19, 11-20 (1991).
33. Azmitia E. C., Whitaker-Azmitia P. M., "Psychopharmacology: The Fourth Generation of Progress," ed. by Bloom F. E., Kupfer D. J., Plenum Press, New York, 1995, pp. 443-449.
34. Greeson J. M., Sanford B., Monti D. A., Psychopharmacology, 153, 402-414 (2001).
35. Lenoir S., Degenring F. H., Saller R., Phytomedicine, 6, 141-146 (1999).
36. Ellis K. A., Slough C., Vitetta L., Heinrich K., Nathan P. J., Behav. Pharmacol., 12, 173-182 (2001).
37. Mueller W. E., Singer A., Wonnemann M., Hafner U., Rolli M., Schaefer C., Pharmacopsychiatry, 31, 16-21 (1998).
38. Butterweck V., Böckers T., Korte B., Wittkowski W., Winterhoff H., Brain Res., 930, 21-29 (2002).
39. Buchholzer M. L., Dvorak C., Chatterjee S.S., Klein J., J. Pharmacol. Exp. Ther., 301, 714-719 (2002).
40. Hunt E. J., Lester C. E., Lester E. A., Tackett R. L., Life Sci., 69, 181-190 (2001).
41. Gouni-Berthold I., Berthold H. K., Am. Heart J., 143, 356-365 (2002).
42. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A., Lancet, 356, 1627-1631 (2000).